Last Posted: Oct 01, 2019
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy- A Secondary Analysis of the TAILORx Randomized Clinical Trial
JA Sparano et al, JAMA Oncology, September 30, 2019 - Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
J Staaf et al, September 30, 2019 - A polygenic risk score for breast cancer in U.S. Latinas and Latin-American women.
Shieh Yiwey et al. Journal of the National Cancer Institute 2019 Sep - Choosing Breast Cancer Risk Models: Importance of Independent Validation
M Gail. JNCI, September 26, 2019 - Polygenic risk scores for breast cancer risk prediction: Lessons learned and future opportunities
JR Palmer et al, JNCI, September 25, 2019 - Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer
GP Watt et al, JAMA Network Open, January 27, 2019 - Assessing the medical workforces perceived barriers to the prescription of risk-reducing medication for women at high-risk of breast cancer.
Sutherland Sarah et al. The breast journal 2019 25(1) 34-40 - Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns Dana et al. Journal of women's health (2002) 2017 26(6) 702-706 - Diagnostic utility of epigenetics in breast cancer - A review.
Bhat Showkat Ahmad et al. Cancer treatment and research communications 2019 19100125 - Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
Damkier Per et al. Pharmacogenomics 2017 Jun 18(8) 753-754
.jpg)
No hay comentarios:
Publicar un comentario